ANDA 202824, held by Accord Hlthcare. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 202824 (Doxazosin Mesylate), held by Accord Hlthcare, was first approved by FDA on Jun 11, 2014, with 2 approved supplements and 0 published complete response letters.
Doxazosin tablets, USP are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 11, 2014 | Original application | Approved | None posted |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Sep 26, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 21, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 11, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters